DSM buys Pentapharm
This article was originally published in The Tan Sheet
Executive Summary
DSM announces Aug. 29 the closing of its deal to buy 100% of Pentapharm Holding's shares, saying it "fits well" with the firm's 2010 strategy to "focus on accelerating and innovative growth." The firm says the official closing represents the "the first major milestone in the joint future and officially starts the cooperative integration activities." DSM does not expect any immediate changes for any of the internal or external stakeholders and all Pentapharm contact persons will remain the same for the time being, the firm states...